Cambridge Healthtech Institute’s 4th Annual
Antibody-Based Therapies
Translating Breakthrough Therapies into the Clinic
17 November 2026
The Antibody-Based Therapies conference brings together innovators advancing novel mechanisms, formats, and combinations beyond traditional IgG. Program themes span complement-targeting and engineered isotype therapies, immunocytokines and cytokine mimetics, and antibody-guided radiopharmaceuticals, ADCs, and degraders. Discussions will emphasise the translation of emerging targets and complex conjugates into the clinic, manage safety liabilities, and integration of these modalities into rational combination strategies.
Coverage will include, but is not limited to:
BEYOND IGG: RADIOPHARMACEUTICALS, ADCS, AND DEGRADERS—MOVING FROM CONCEPT TO CLINICAL TRANSLATION
- Antibody-guided radiopharmaceuticals vs small-molecule radioligands
- Next-generation ADCs and bioconjugates
- Antibody-based targeted protein degradation: bioPROTACs, DACs and extracellular degraders (LYTACs)
- Comparing and Combining ADCs, radiopharmaceuticals, TCEs, degraders, and checkpoint inhibitors
IMMUNOCYTOKINES, CYTOKINE MIMETICS, AND CONDITIONALLY ACTIVE CYTOKINES
- Immunocytokines and fusions
- Cytokine mimetics via multispecific antibodies
- Conditionally active/masked cytokines
- Combining immunocytokines with bispecific TCEs
TRANSLATING NOVEL TARGETS AND NEW MECHANISMS OF ACTION INTO THE CLINIC
- From dark antigens and neoantigens to druggable antibody targets
- TNFR superfamily agonists and immune activation
- Expanding target space from oncology to other indications
COMPLEMENT TARGETING & ENGINEERED ANTIBODIES FOR AUTOIMMUNE AND INFLAMMATORY DISEASES
- Antagonist antibodies targeting Fc receptors and complement pathways
- IgA-based therapeutics: engaging neutrophilsand macrophages
- T cell engagers and engineered CAR-T therapies
- Bispecific complement modulators and next-generation pathway engineering
- Immune modulation versus depletion
The deadline for priority consideration is 9 April 2026.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: